PMID- 28534152 OWN - NLM STAT- MEDLINE DCOM- 20180410 LR - 20181113 IS - 1573-7373 (Electronic) IS - 0167-594X (Print) IS - 0167-594X (Linking) VI - 133 IP - 1 DP - 2017 May TI - Cerebrospinal fluid dissemination of high-grade gliomas following boron neutron capture therapy occurs more frequently in the small cell subtype of IDH1(R132H) mutation-negative glioblastoma. PG - 107-118 LID - 10.1007/s11060-017-2408-x [doi] AB - We have used boron neutron capture therapy (BNCT) to treat patients in Japan with newly diagnosed or recurrent high-grade gliomas and have observed a significant increase in median survival time following BNCT. Although cerebrospinal fluid dissemination (CSFD) is not usually seen with the current standard therapy of patients with glioblastoma (GBM), here we report that subarachnoid or intraventricular CSFD was the most frequent cause of death for a cohort of our patients with high-grade gliomas who had been treated with BNCT. The study population consisted of 87 patients with supratentorial high-grade gliomas; 41 had newly diagnosed tumors and 46 had recurrent tumors. Thirty of 87 patients who were treated between January 2002 and July 2013 developed CSFD. Tumor histology before BNCT and immunohistochemical staining for two molecular markers, Ki-67 and IDH1(R132H), were evaluated for 20 of the 30 patients for whom pathology slides were available. Fluorescence in situ hybridization (FISH) was performed on 3 IDH1(R132H)-positive and 1 control IDH1(R132H)-negative tumors in order to determine chromosome 1p and 19q status. Histopathologic evaluation revealed that 10 of the 20 patients' tumors were IDH1(R132H)-negative small cell GBMs. The remaining patients had tumors consisting of other IDH1(R132H)-negative GBM variants, an IDH1(R132H)-positive GBM and two anaplastic oligodendrogliomas. Ki-67 immunopositivity ranged from 2 to 75%. In summary, IDH1(R132H)-negative GBMs, especially small cell GBMs, accounted for a disproportionately large number of patients who had CSF dissemination. This suggests that these tumor types had an increased propensity to disseminate via the CSF following BNCT and that these patients are at high risk for this clinically serious event. FAU - Kondo, Natsuko AU - Kondo N AD - Particle Radiation Oncology Research Center, Kyoto University Research Reactor Institute, Sennan-gun, Osaka, Japan. nkondo@rri.kyoto-u.ac.jp. FAU - Barth, Rolf F AU - Barth RF AD - Department of Pathology, The Ohio State University Medical Center, Columbus, OH, USA. FAU - Miyatake, Shin-Ichi AU - Miyatake SI AD - Department of Neurosurgery, Osaka Medical College, Takatsuki City, Osaka, Japan. FAU - Kawabata, Shinji AU - Kawabata S AD - Department of Neurosurgery, Osaka Medical College, Takatsuki City, Osaka, Japan. FAU - Suzuki, Minoru AU - Suzuki M AD - Particle Radiation Oncology Research Center, Kyoto University Research Reactor Institute, Sennan-gun, Osaka, Japan. FAU - Ono, Koji AU - Ono K AD - Particle Radiation Oncology Research Center, Kyoto University Research Reactor Institute, Sennan-gun, Osaka, Japan. FAU - Lehman, Norman L AU - Lehman NL AD - Department of Pathology, The Ohio State University Medical Center, Columbus, OH, USA. nllehman@yahoo.com. LA - eng GR - R01 NS081125/NS/NINDS NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural PT - Research Support, Non-U.S. Gov't DEP - 20170522 PL - United States TA - J Neurooncol JT - Journal of neuro-oncology JID - 8309335 RN - EC 1.1.1.41 (Isocitrate Dehydrogenase) RN - EC 1.1.1.42. (IDH1 protein, human) SB - IM MH - Adolescent MH - Adult MH - Aged MH - *Boron Neutron Capture Therapy MH - Brain/diagnostic imaging MH - Brain Neoplasms/genetics/mortality/pathology/*radiotherapy MH - Cerebrospinal Fluid Leak/diagnostic imaging/*etiology/genetics/mortality MH - Female MH - Follow-Up Studies MH - Genetic Predisposition to Disease MH - Glioma/genetics/mortality/pathology/*radiotherapy MH - Humans MH - Isocitrate Dehydrogenase/*genetics MH - Male MH - Middle Aged MH - Neoplasm Grading MH - Radiotherapy Dosage MH - Spinal Cord/diagnostic imaging MH - Survival Analysis PMC - PMC5786264 MID - NIHMS878667 OTO - NOTNLM OT - Anaplastic oligodendroglioma OT - Boron neutron capture therapy OT - Cerebrospinal fluid dissemination OT - High-grade glioma OT - Small cell glioblastoma EDAT- 2017/05/24 06:00 MHDA- 2018/04/11 06:00 PMCR- 2018/05/22 CRDT- 2017/05/24 06:00 PHST- 2016/10/28 00:00 [received] PHST- 2017/04/01 00:00 [accepted] PHST- 2017/05/24 06:00 [pubmed] PHST- 2018/04/11 06:00 [medline] PHST- 2017/05/24 06:00 [entrez] PHST- 2018/05/22 00:00 [pmc-release] AID - 10.1007/s11060-017-2408-x [pii] AID - 10.1007/s11060-017-2408-x [doi] PST - ppublish SO - J Neurooncol. 2017 May;133(1):107-118. doi: 10.1007/s11060-017-2408-x. Epub 2017 May 22.